Antimicrobial Resistance in India Needs Integrated Action

India’s AMR Crisis Extends Beyond Antibiotic Overuse

Antimicrobial Resistance in India Needs Integrated Action: A recent study by the Indian Council of Medical Research (ICMR) highlights the growing threat posed by antimicrobial resistance (AMR) in India. Infections caused by resistant Gram-negative bacteria were associated with higher mortality and greater antibiotic costs than infections caused by drug-susceptible strains.

The findings also show that India’s AMR problem cannot be attributed to antibiotic overuse alone. Delayed diagnosis, healthcare-associated transmission, invasive medical devices, recent surgery and weaknesses in infection prevention also contribute significantly.

Understanding Gram-negative Bacteria

Gram-negative bacteria have a thin peptidoglycan cell wall and an outer membrane containing lipopolysaccharides. They appear pink or red under Gram staining and can cause infections involving the lungs, urinary tract, wounds and bloodstream.

Important hospital-associated pathogens include Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.

Static GK Tip: Gram staining broadly divides bacteria into Gram-positive and Gram-negative groups based on differences in their cell-wall structure.

Why Carbapenem Resistance Matters

Carbapenems are powerful antibiotics commonly used to treat severe bacterial infections. They are often reserved for situations where other antibiotics may not work.

When bacteria develop carbapenem resistance, treatment options become considerably more limited. This makes carbapenem-resistant infections particularly concerning in critically ill and bloodstream-infected patients.

Key Findings of the ICMR Study

The study was conducted through the ICMR Antimicrobial Resistance Surveillance Network across 20 tertiary-care hospitals between April 2022 and April 2025.

Mortality was consistently higher among patients with carbapenem-resistant infections involving the four major pathogens studied. The relative risk of death ranged from 1.16 to 1.43 times higher.

More than 61% of Gram-negative infections examined in the study were carbapenem-resistant.

However, researchers caution that resistance should not automatically be treated as the sole cause of death. Disease severity, treatment timing, source control and individual patient factors also influence outcomes.

Healthcare Transmission Is a Major Concern

The study found that more than 85% of bloodstream infections were healthcare-associated. This highlights the importance of infection prevention within hospitals.

Key measures include hand hygiene, environmental cleaning, surgical infection prevention, appropriate use and early removal of invasive devices, and surveillance of healthcare-associated infections.

Static GK Tip: Infection prevention and control (IPC) aims to prevent infections from spreading within healthcare settings and is a major component of AMR management.

Economic Burden of Resistant Infections

Antibiotic treatment for resistant infections was found to cost approximately 1.1 to 2 times more than treatment for susceptible infections under the study’s narrow cost assessment.

Importantly, researchers considered only the cost of antibiotics available through the Jan Aushadhi scheme. Expenses such as ICU care, hospital beds, diagnostic tests, procedures, supportive treatment and consultation fees were excluded.

Therefore, the actual financial burden of resistant infections is likely to be substantially greater.

Ceftazidime-avibactam Shows a Positive Signal

The study associated ceftazidime-avibactam with better outcomes in some resistant E. coli and K. pneumoniae infections, including bloodstream infections.

However, researchers describe this as a signal rather than definitive evidence of superiority. Since the study was observational, it could not completely account for factors such as disease severity, treatment timing and different resistance mechanisms.

The findings therefore reinforce the need for accurate and rapid diagnostics rather than automatically shifting to newer or broader antibiotics.

Antibiotics Cannot Replace Prevention

The study reinforces an important principle: newer antibiotics alone cannot solve AMR. Preventing infections can reduce the need for antibiotics in the first place and limit opportunities for resistant organisms to spread.

Hospitals need strong antimicrobial stewardship, ensuring that the narrowest effective antibiotic is selected for an appropriate duration. The objective should be to preserve existing medicines while ensuring access to newer antimicrobials when genuinely required.

Integrated Strategy for India

India’s response to AMR requires coordinated action across surveillance, diagnosis, prescribing and infection control.

First, surveillance should connect laboratory results with treatment, patient outcomes and mortality. Second, rapid diagnostics should help distinguish bacterial infections from non-bacterial illnesses and identify resistance earlier.

Third, antimicrobial stewardship should become routine clinical practice. Finally, infection prevention must receive the same priority as antibiotic prescribing, while newer antimicrobials should remain responsibly accessible.

Significance

The ICMR findings demonstrate that carbapenem resistance is both a clinical and economic challenge. India’s AMR response must therefore move beyond simply developing stronger antibiotics.

Preventing healthcare-associated infections, improving diagnosis, using antibiotics responsibly and preserving the effectiveness of existing medicines are essential for controlling the long-term AMR threat.

Static Usthadian Current Affairs Table

Antimicrobial Resistance in India Needs Integrated Action: